Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK
Summary
Hangzhou Innogate Pharma, kinase inhibitor patent, CDK TRK
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Polycyclic compound acting as kinase inhibitor
Grant US12589092B2 Kind: B2 Mar 31, 2026
Assignee
Hangzhou Innogate Pharma Co., Ltd.
Inventors
Hancheng Zhang, Xin Cheng, Wei Jia, Congcong Cai
Abstract
The present invention provides a class of compounds containing tricyclic heteroaryl groups. Specifically, the present invention provides compounds of the structure represented by the following formula (I) (the definition of each group is described in the specification), pharmaceutical compositions containing the compounds of formula (I), as well as optical isomers, pharmaceutical acceptable salts, prodrugs, deuterated derivatives, hydrates, solvates, etc. The compounds of formula (I) can effectively inhibit protein kinases including CDK and/or TRK, thereby playing a role in the treatment of various tumors and related disease.
CPC Classifications
A61K 31/4375 A61K 31/4985 A61K 31/519 A61P 35/00
Filing Date
2021-01-11
Application No.
17757944
Claims
20
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.